Safety data sheet
Standardized safety protocols and material specifications for professional use.
Certificate of Analysis
Purity verified via High-Performance Liquid Chromatography (HPLC) for #myo-semaglutide-5mg
Semaglutide (5mg)
Ultra High >99.5% Purity
Authorized Resellers
Available through our trusted partners
123peptide.com
Netherlands · Europe
local_shipping2-3 Business Days
Depeptidenwinkel.com
Netherlands · Europe
local_shipping2-3 Business Days
Scientific Background
Semaglutide has become the gold standard for many people serious about sustainable weight loss. With once-weekly dosing and clinical proof of 10–15% average body weight reduction (often 15–20%+ in strong responders), it's one of the most effective tools available for appetite control and metabolic reset.
Semaglutide is a long-acting GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1, powerfully reducing hunger, slowing gastric emptying, and improving insulin sensitivity for significant, sustained weight loss.
Start low with this 5mg vial, titrate smoothly, and watch the scale move week after week. Whether you're coming from diet struggles or want to accelerate your progress, Semaglutide delivers real, life-changing results.
Intended Research Use
- Dramatic appetite and food craving reduction
- Slowed gastric emptying for longer-lasting fullness
- Improved insulin sensitivity and blood sugar control
- Clinically proven 10–15% average weight loss
- GLP-1 receptor binding and metabolic pathway research
menu_bookScientific Publications
N Engl J Med (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33567185/
JAMA (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33625476/
JAMA (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
open_in_newhttps://pubmed.ncbi.nlm.nih.gov/33625476/
Clinical Evidence: In phase 3 clinical trials, semaglutide at maintenance doses led to 10–15% average body weight loss over 68 weeks, with many participants achieving 15–20%+ reduction when combined with lifestyle changes. It significantly reduced visceral fat, improved HbA1c, blood pressure, and lipid profiles.
FOR RESEARCH USE ONLY. This product is intended for laboratory research purposes only and is not for human consumption, medical, or diagnostic use.
Possible stacks with other peptides
Synergistic combinations for enhanced research outcomes
Clinical research suggests combining Semaglutide with complementary peptides can enhance weight management outcomes. These combinations target multiple metabolic pathways for amplified fat-burning and appetite control effects.
Cagrilintide (5mg vial)
arrow_forwardmyo-cagrilintide-5mg
Combines GLP-1 with amylin analog for enhanced satiety and superior weight loss synergy (CagriSema approach).
AOD-9604 (5mg vial)
arrow_forwardmyo-hgh-fragment-aod-9604-5mg
Pairs appetite control with targeted fat metabolism for localized contouring support.
Retatrutide (10mg vial)
arrow_forwardmyo-retatrutide-10mg
Adds GIP/glucagon activation to semaglutide's GLP-1 for amplified fat-burning and energy effects.
CagriSema (Semaglutide + Cagrilintide) (5mg + 5mg vial)
arrow_forwardmyo-semaglutide-plus-cagrilintide-5mg-5mg
Semaglutide combined with cagrilintide's amylin action for superior dual-mechanism weight loss — the logical progression from standalone Semaglutide research.
Tirzepatide 10mg (10mg vial)
arrow_forwardmyo-tirzepatide-10mg
Dual GLP-1/GIP agonist with superior glycemic control and higher weight loss ceiling — compared with Semaglutide in head-to-head clinical research.
Cycling Note: Continue for sustained weight loss; clinical trials support 68+ weeks of continuous use for optimal results.
